Investigational drug · Phase 3
Experimental: Sacubitril
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Essential Hypertension.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
15
Any phase or sponsor naming "Experimental: Sacubitril"
First trial start
2023
Jun 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Experimental: Sacubitril", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Experimental: Sacubitril" as an intervention, largest first.
- Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)Pivotal-lookingRecruiting
Silesian Centre for Heart DiseasesAcademic, hospital or other
NCT05465031 · 600 participants (planned) · Start Apr 17, 2024 · Primary completion Dec 2027
Drug: Sacubitril-valsartan; Placebo · For: Breast Cancer; Neoplasm, Breast; Breast Diseases and 10 more
Sites: Opole, Poland; Gliwice, Poland; Zabrze, Poland · 4 sites in all
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial InfarctionPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT05764057 · 450 participants (planned) · Start Jun 12, 2023 · Primary completion Oct 12, 2026
Drug: Dapagliflozin propanediol (FORXIGA™/FARXIGA™1); Placebo comparator · For: AMI; STEMI; NSTEMI and 1 more
Sites: Paris, France
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With AmlodipinePivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07704684 · 376 participants · Start Jun 28, 2023 · Primary completion Aug 26, 2025
Drug: Experimental: Sacubitril/Allisartan and Amlodipine Group; Active Comparator: Amlodipine Group · For: Essential Hypertension
Sites: Beijing, China
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/AllisartanPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07704697 · 346 participants · Start Nov 23, 2024 · Primary completion Nov 10, 2025
Drug: Experimental: Sacubitril/Allisartan and Amlodipine Group; Active Comparator: Sacubitril/Allisartan Group · For: Essential Hypertension
Sites: Beijing, China
- Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic NephropathyPivotal-lookingStatus unknown
Sichuan Academy of Medical SciencesAcademic, hospital or other
NCT06501651 · 297 participants (planned) · Start Aug 1, 2024 · Primary completion Apr 10, 2025
Drug: Sacubitril/Valsartan; Valsartan · For: Essential Hypertension; Type 2 Diabetes; Nephropathy
Sites: Chengdu, China
- Early Treatment of ARNI on Myocardial Remodeling and ProgressPivotal-lookingStatus unknown
RenJi HospitalAcademic, hospital or other
NCT04342351 · 280 participants (planned) · Start May 1, 2020 · Primary completion May 1, 2021
Drug: sacubitril/valsartan; perindopril · For: Myocardial Infarction
Sites: Shanghai, China
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "Pivotal-lookingStatus unknown
Instituto Nacional de Cardiologia Ignacio ChavezAcademic, hospital or other
NCT05580510 · 160 participants (planned) · Start Feb 6, 2023 · Primary completion Jul 28, 2023
Drug: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID; Empagliflozin 10 MG OD · For: Congenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection Fraction
Sites: Mexico City, Mexico
- Effects and Safety of Sacubitril/Valsartan on Refractory HypertensionPivotal-lookingStatus unknown
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT05545059 · 138 participants (planned) · Start Sep 24, 2022 · Primary completion Oct 28, 2022
Drug: Sacubitril/valsartan; valsartan · For: Resistant Hypertension
Sites: Guangzhou, China
- Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.Pivotal-lookingStatus unknown
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT04929600 · 120 participants (planned) · Start Nov 28, 2021 · Primary completion Jun 2023
Drug: sacubitril/valsartan; Amlodipine · For: Hypertension; Left Ventricular Hypertrophy
Sites: Shanghai, China
- Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)Pivotal-lookingCompleted
Qian FengAcademic, hospital or other
NCT07130175 · 118 participants · Start Dec 31, 2022 · Primary completion Dec 31, 2024
Drug: Guideline-Directed Medical Therapy (GDMT) · For: Polymorphic Ventricular Tachycardia; Heart Failure
Sites: Zhangjiakou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Essential Hypertension
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- AD-227APhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227BPhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227CPhase 31 trial
Addpharma Inc. · Essential Hypertension
- ATB-1011Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1012Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1013Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.